OR9Q1 Antibody

What is OR9Q1 and what role does it play in olfactory signaling?

OR9Q1 (Olfactory receptor 9Q1) is a member of the olfactory receptor family, which comprises G-protein-coupled receptors (GPCRs) with seven transmembrane domains. These receptors interact with odorant molecules in the nasal cavity to initiate neuronal responses that ultimately trigger smell perception . As part of the largest gene family in the genome, OR9Q1 contributes to the remarkable diversity of odor recognition capabilities . The protein encoded by the OR9Q1 gene functions through G-protein-mediated signal transduction, activating second messenger pathways upon ligand binding. OR9Q1, like other olfactory receptors, has a single coding exon gene structure, which is a distinctive characteristic of this receptor family .

What are the standard detection methods for OR9Q1 in research applications?

Multiple approaches exist for detecting OR9Q1 in experimental settings. Western blotting (WB) can be performed with a starting dilution of 1:1000 for the primary antibody, while immunohistochemistry on paraffin-embedded tissues (IHC-P) typically begins with dilutions between 1:50 and 1:100 . For flow cytometry applications (FACS), initial dilutions of 1:10 to 1:50 are recommended . Immunofluorescence (IF) can be conducted with dilution ranges of 1:200 to 1:1000, and ELISA applications may use higher dilutions up to 1:10000 . These methods can be applied to detect OR9Q1 in human and mouse samples, as several commercially available antibodies show cross-reactivity between these species .

What biological samples are appropriate for OR9Q1 investigation?

OR9Q1 can be studied in various biological materials. Tissue homogenates, particularly from olfactory tissues, provide a native context for examining receptor expression and function . Cell lysates, especially from cell lines that endogenously express the receptor or have been transfected with OR9Q1 expression constructs, are commonly used for biochemical analyses . Other biological fluids may also be appropriate depending on the research question . Notably, certain cell lines like HuH7 (human hepatocellular carcinoma cells) have been identified as expressing functional OR9Q1, making them potentially valuable experimental models .

What are the key technical specifications for OR9Q1 antibodies?

Commercial OR9Q1 antibodies possess several important technical characteristics. Most are derived from rabbits immunized with synthetic peptides corresponding to the C-terminal region of human OR9Q1 . Polyclonal antibodies against OR9Q1 typically recognize both human and mouse orthologs, making them versatile across species . The antibodies are generally supplied in liquid form, often in PBS buffer containing preservatives like 50% glycerol, 0.5% BSA, and 0.02% sodium azide . For optimal stability, storage at -20°C or -80°C is recommended, with aliquoting advised to avoid repeated freeze-thaw cycles . The antibodies are typically affinity-purified using epitope-specific immunogen chromatography to ensure specificity .

How is OR9Q1 classified within the olfactory receptor family?

OR9Q1 belongs to the extensive olfactory receptor family, which constitutes the largest gene family in the mammalian genome . As indicated by its systematic name, OR9Q1 belongs to subfamily 9, with "Q1" designating its specific member status. The nomenclature for olfactory receptors is species-specific, with independent naming systems across organisms . In databases, OR9Q1 is identified by the UniProt accession number Q8NGQ5 and the entry name OR9Q1_HUMAN . The gene encoding this receptor is officially designated as OR9Q1 (gene symbol), with the KEGG database entry hsa:219956 providing pathway information .

How can I optimize functional expression systems for OR9Q1 studies?

Selecting an appropriate cell line is crucial for successful OR9Q1 functional studies. Research has shown that HuH7 cells (human hepatocellular carcinoma cells) can effectively express functional OR9Q1, while the commonly used HEK293 cells may not support proper receptor function . When designing expression systems, consider co-transfecting accessory factors that enhance cell surface trafficking of olfactory receptors, such as RTP1S (Receptor Transporting Protein 1, Short) . Additionally, incorporating reporter constructs like CRE/luc2P allows for monitoring receptor activation through luciferase assays .

For experimental design, include proper controls such as empty vector transfections alongside OR9Q1-expressing constructs . Normalize responses using constitutively expressed reporters (e.g., pRL-CMV) to account for transfection efficiency variations . When testing potential ligands, prepare dose-response curves with concentrations ranging from nanomolar to high micromolar to capture the full activation profile . The culture conditions, transfection reagents, and buffer compositions should be optimized for each cell line, as these parameters significantly impact functional expression outcomes .

What approaches can help identify ligands for OR9Q1?

Given that OR9Q1 has been described as an orphan receptor in some contexts, identifying its ligands represents an important research direction . Several methodological strategies can be employed:

• High-throughput screening using reporter assays in cells functionally expressing OR9Q1, such as HuH7 cells, which have demonstrated capacity for OR9Q1 functional expression

• Testing odorant mixtures before individual compounds to increase the probability of detecting responses, as demonstrated for other orphan receptors like OR51T1

• Implementing calcium imaging or cAMP assays to detect receptor activation following exposure to candidate ligands

• Comparing responses across multiple cell lines, as the cellular context significantly impacts receptor functionality; OR9Q1 shows differential activation patterns between cell types

• Consider using dose-dependent response curves with proper controls to validate ligand specificity, as non-specific effects can confound interpretation

When conducting these experiments, it's essential to address the high basal activity that some ORs exhibit in heterologous systems, which can mask ligand-induced responses . Manipulating cAMP metabolism through co-expression of phosphodiesterases like PDE1C might help reduce background noise and improve detection sensitivity .

How should I troubleshoot OR9Q1 detection issues in Western blotting?

When facing difficulties in OR9Q1 detection via Western blotting, several optimization strategies can be implemented:

• Sample preparation: OR9Q1, being a transmembrane protein, requires careful extraction procedures. Use detergent-based lysis buffers containing 1-2% Triton X-100 or CHAPS to effectively solubilize membrane proteins. Avoid boiling samples for extended periods, as this can cause GPCR aggregation.

• Antibody selection: Begin with recommended dilutions (1:1000 for Western blotting) , but consider titrating from 1:500 to 1:2000 to determine optimal concentration . The epitope accessibility may vary depending on sample processing.

• Blocking conditions: Test different blocking agents (5% non-fat milk versus 5% BSA) as membrane proteins sometimes show better detection with BSA-based blockers.

• Membrane protein considerations: Include positive controls using known membrane proteins of similar size to verify transfer efficiency. Use mild transfer conditions with methanol-containing buffers to improve transfer of hydrophobic proteins.

• Detection enhancement: Consider using signal enhancement systems or longer exposure times, as OR9Q1 may be expressed at low levels in some samples.

If non-specific bands appear, validate specificity using peptide competition assays with the immunizing peptide derived from the C-terminal region of OR9Q1 . Additionally, compare results across different antibody lots and sources to confirm consistent detection patterns.

What are the key considerations for quantitative analysis of OR9Q1 expression?

Accurate quantification of OR9Q1 expression requires careful experimental design and appropriate controls:

When using ELISA-based quantification, samples should be diluted to fall within the mid-range of the assay kit's detection range (0.156-10 ng/ml) for optimal accuracy . It's important to note that comparisons between different detection methods may yield inconsistent results due to variations in epitope accessibility and antibody affinities. When analyzing expression across multiple samples, maintain consistent experimental conditions to minimize technical variability. For long-term studies, consider creating internal laboratory standards to normalize between experimental batches.

How does OR9Q1 basal activity affect experimental outcomes?

OR9Q1, like several other olfactory receptors, may exhibit high basal (constitutive) activity in heterologous expression systems, which can significantly impact experimental outcomes . This basal activity creates a high background signal that potentially masks ligand-induced responses, complicating the identification of specific agonists .

To address this challenge, researchers can implement several strategies:

• Select appropriate cellular backgrounds with lower basal activity for the specific receptor

• Co-express phosphodiesterases like PDE1C to reduce background cAMP levels

• Use normalized reporting systems that account for baseline activity

• Implement statistical approaches that distinguish significant changes from baseline fluctuations

Understanding and managing this basal activity is particularly important when investigating orphan receptors like OR9Q1, where identifying physiological ligands remains a research priority.

What are the optimal immunohistochemistry protocols for OR9Q1 detection?

For successful immunohistochemical detection of OR9Q1 in tissue samples, careful consideration of fixation, antigen retrieval, and antibody incubation conditions is essential:

• Tissue preparation: Fix tissues in 4% paraformaldehyde for 24 hours, followed by paraffin embedding using standard protocols. For cryosections, fix tissues briefly (10-20 minutes) prior to freezing to preserve epitope integrity.

• Sectioning: Prepare 5-7 μm sections for optimal antibody penetration while maintaining tissue architecture.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) is recommended, typically at 95-100°C for 20 minutes. This step is crucial as OR9Q1, being a transmembrane protein, may have epitopes masked during fixation.

• Blocking: Use 5-10% normal serum (matched to secondary antibody host) with 0.1-0.3% Triton X-100 for permeabilization. Include an avidin-biotin blocking step if using biotin-based detection systems.

• Primary antibody incubation: Apply OR9Q1 antibody at dilutions between 1:50 and 1:100 . Incubate overnight at 4°C for optimal binding. Consider testing both C-terminal and N-terminal targeting antibodies as epitope accessibility may vary by preparation method.

• Detection system: Employ polymer-based detection systems or tyramide signal amplification for enhanced sensitivity, particularly in tissues with low expression levels.

• Controls: Include both negative controls (primary antibody omission, non-immune IgG) and positive controls (tissues known to express OR9Q1) in each experimental run.

For fluorescent detection, minimize autofluorescence by including a brief treatment with 0.1% Sudan Black B in 70% ethanol after secondary antibody incubation, particularly when working with tissues containing lipofuscin.

How should I design immunofluorescence experiments for OR9Q1 localization studies?

When conducting immunofluorescence studies to examine OR9Q1 subcellular localization, implement the following detailed protocol:

• Cell preparation: For cultured cells, grow on coated coverslips to 70-80% confluence. Fix with 4% paraformaldehyde for 15 minutes at room temperature. For tissue sections, use freshly prepared cryosections or paraffin sections with appropriate antigen retrieval.

• Permeabilization: Use 0.2% Triton X-100 in PBS for 10 minutes to allow antibody access to intracellular epitopes. For membrane proteins like OR9Q1, gentler permeabilization with 0.1% saponin may better preserve membrane structures.

• Blocking: Incubate samples with 5% normal serum and 1% BSA in PBS for 1 hour at room temperature to minimize non-specific binding.

• Primary antibody: Apply OR9Q1 antibody at dilutions between 1:200 and 1:1000 . Incubate overnight at 4°C in a humidified chamber.

• Co-localization markers: Include antibodies against organelle markers to determine subcellular localization:

  • Plasma membrane: Na+/K+ ATPase or wheat germ agglutinin

  • Endoplasmic reticulum: Calnexin or PDI

  • Golgi apparatus: GM130 or TGN46

  • Endocytic compartments: Rab5 (early endosomes) or Rab7 (late endosomes)

• Secondary antibody: Use fluorophore-conjugated secondaries with minimal spectral overlap. Incubate for 1 hour at room temperature, protected from light.

• Nuclear counterstain: Apply DAPI (1 μg/ml) for 5 minutes before final washes.

• Mounting: Use anti-fade mounting medium to preserve fluorescence intensity during imaging and storage.

For live-cell imaging of surface-expressed OR9Q1, consider using antibodies targeting extracellular epitopes (often N-terminal regions) without permeabilization . This approach allows for distinguishing between total and surface-expressed receptor populations.

What cell-based functional assays are appropriate for studying OR9Q1 activation?

Several functional assays can be employed to study OR9Q1 activation in cellular systems:

• cAMP-dependent luciferase reporter assays: Transfect cells with OR9Q1 along with a CRE-luciferase reporter construct (e.g., CRE/luc2P pGL4.29) and a constitutive reporter (e.g., pRL-CMV) for normalization . This sensitive approach detects changes in cAMP levels following receptor activation and can be used for dose-response studies with potential ligands.

• Calcium imaging: Load OR9Q1-expressing cells with calcium-sensitive dyes (Fluo-4, Fura-2) or co-express genetically encoded calcium indicators (GCaMPs) to monitor calcium flux upon receptor activation in real-time.

• BRET/FRET-based assays: Employ bioluminescence or fluorescence resonance energy transfer sensors to detect conformational changes in the receptor or interactions with downstream signaling partners.

• Impedance-based assays: Monitor whole-cell responses using label-free systems that detect morphological changes following receptor activation.

When selecting an appropriate cell background, consider that HuH7 cells have demonstrated the capacity to functionally express OR9Q1, unlike some common expression systems like HEK293 cells . Co-transfection with accessory factors such as RTP1S (Receptor Transporting Protein 1, Short) and Gαolf can enhance functional expression . For assay validation, include positive controls with receptors of known ligand specificity expressed in the same system, as well as negative controls using mock-transfected cells .

How can I validate OR9Q1 antibody specificity for my experimental system?

Comprehensive validation of OR9Q1 antibody specificity is essential for generating reliable experimental data:

• Peptide competition assays: Pre-incubate the antibody with excess immunizing peptide (derived from the C-terminal region of human OR9Q1) before application to samples . Specific signals should be substantially reduced or eliminated.

• Genetic approaches: Compare antibody staining in samples with OR9Q1 knockdown (siRNA, shRNA) or knockout (CRISPR-Cas9) to wild-type samples. Specific signals should decrease proportionally to reduction in expression level.

• Heterologous expression: Overexpress tagged OR9Q1 in a cell line with minimal endogenous expression. Compare detection patterns between tag-specific and OR9Q1-specific antibodies.

• Multiple antibody validation: Use antibodies recognizing different epitopes of OR9Q1 and compare staining patterns. Consistent results across antibodies increase confidence in specificity.

• Mass spectrometry: Perform immunoprecipitation followed by mass spectrometry to confirm that the antibody captures the intended target protein.

• Cross-reactivity assessment: Test the antibody against closely related olfactory receptors, particularly those with high sequence homology in the C-terminal region, to ensure specificity within the OR family.

When validating for specific applications, include application-relevant controls. For immunofluorescence, include absorption controls and secondary-only controls . For Western blotting, verify that the detected band appears at the expected molecular weight for OR9Q1 (approximately 35-40 kDa), accounting for potential post-translational modifications.

What are the key considerations for using OR9Q1 ELISA kits in research?

When working with ELISA kits for OR9Q1 quantification, several methodological considerations can optimize results:

• Sample preparation: Process tissue homogenates, cell lysates, or biological fluids according to kit-specific instructions . For tissue homogenates, use buffer systems that effectively solubilize membrane proteins without denaturing the target epitopes.

• Dilution optimization: Test multiple sample dilutions to ensure measurements fall within the kit's detection range (0.156-10 ng/ml) . Samples with high OR9Q1 content may require serial dilutions to avoid saturation effects.

• Standard curve preparation: Carefully reconstitute the lyophilized standard and prepare a fresh dilution series for each experimental run . Plot standard curves using appropriate regression models (typically 4-parameter logistic regression).

• Technical replicates: Run samples in duplicate or triplicate to assess technical variability and identify potential outliers.

• Controls and normalization: Include internal laboratory controls across multiple plates/experiments to normalize between batches. Consider normalizing to total protein concentration for comparing across different sample types.

• Storage and stability: Store kits at 4°C upon receipt and follow the manufacturer's stability guidelines . Note that kit components typically have a validity period of 6 months, with activity loss rates less than 5% within this timeframe under appropriate storage conditions .

To minimize performance fluctuations, standardize laboratory conditions and ideally have the same researcher perform the complete assay . Be aware that these kits are optimized for detection of native samples rather than recombinant proteins, which may have different sequences or tertiary structures compared to the native protein .